Desferrithiocin polyether analogues

• US 9,096,553 B2
• Filed: 04/29/2014
• Issued: 08/04/2015
• Est. Priority Date: 04/04/2005
• Status: Active Grant

• Current Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Original Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Inventors: Bergeron, Raymond J. Jr.
• Primary Examiner(s): STOCKTON, LAURA LYNNE
• Application Number:
  US14/264,959
• Publication Number:
  US 20140235680A1
• Time in Patent Office: 462 Days
• Field of Search: 548/201
• US Class Current: 1/1
• CPC Class Codes: A61K 31/426 1,3-Thiazoles
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 39/04 Chelating agents
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C07B 2200/07 Optical isomers
• CPC Class Codes: C07D 277/10 with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• CPC Class Codes: C07D 277/12 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Abstract

Compounds represented by structural formulas described herein, such as Structural Formula (I):

or a pharmaceutically acceptable salt thereof are useful in treating conditions such as metal overload, oxidative stress, and neoplastic and preneoplastic conditions.

Claims

1. A compound represented by Structural Formula (V):

2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (V):

3. A method of treating trivalent metal overload in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by of Structural Formula (V):

4. The method of claim 3, wherein the trivalent metal overload is associated with deposition of the trivalent metal in the tissues of the subject, wherein the trivalent metal is iron or aluminum.

5. The method of claim 3, wherein the trivalent metal overload is iron overload.

6. The method of claim 5, wherein the trivalent metal overload is associated with hemochromatosis.

7. A method of treating transfusional iron overload in a subject comprising administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (V):